Every 424B that Beyond Air, Inc. (XAIR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow XAIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAIR filings page.
Beyond Air, Inc. (XAIR) has filed a resale prospectus covering up to 5,417,538 shares of common stock that may be offered from time to time by selling stockholders. The registered shares consist of 167,011 outstanding shares plus shares issuable upon exercise of pre-funded, Series A and Series B warrants issued in a July 29, 2026 private placement.
Beyond Air is not selling shares in this offering and will not receive proceeds from resales, though it will receive cash if warrants are exercised. The July 31, 2026 private placement raised ~$10.2 million in gross proceeds at combined prices of $5.66–$5.76 per share (or pre-funded warrant) plus common warrants.
The company recently effected a 1-for-20 reverse stock split effective July 13, 2026 to regain Nasdaq bid-price compliance; it is now under a one-year Nasdaq discretionary panel monitor, and future listing deficiencies during this period could lead to an accelerated delisting process. Common shares outstanding were 755,549 as of July 28, 2026 and would be 6,173,087 if all new warrants are fully exercised.
Beyond Air, Inc. has filed a prospectus covering the resale of 524,990 shares of common stock, 3,405,828 shares issuable upon exercise of pre-funded warrants, and 3,930,818 shares issuable upon exercise of common warrants by existing investors. The company will not receive proceeds from these resales, but could receive cash if the warrants are exercised. Shares outstanding were 10,529,344 as of January 22, 2026, rising to 17,865,990 assuming full warrant exercise. Recent developments include a $12.05 million secured note at 15% interest, a $20 million equity purchase agreement with Streeterville Capital, expanded credit from insider lenders, and a binding letter of intent to sell its 85% stake in NeuroNOS Ltd. for cash, XTL Biopharmaceuticals equity, and up to $31.5 million in milestones. LungFit PH has also received European CE mark approval, broadening its approved indications beyond the United States.
Beyond Air, Inc. is registering up to 1,600,000 shares of common stock for resale by Streeterville Capital, LLC. These shares may be issued to Streeterville under a $20 million Equity Purchase Agreement and, in some cases, as share issuances used to offset amounts outstanding under a $12,050,000 secured promissory note. Beyond Air will not receive proceeds from Streeterville’s resale of the registered shares, but may receive cash when it sells stock to Streeterville under the purchase agreement.
As of December 8, 2025, Beyond Air had 8,009,488 shares outstanding and a 4.99% beneficial ownership cap limits Streeterville’s holdings after each put. The company plans to use any cash raised from sales to Streeterville for general corporate purposes, including working capital, commercial operations, repayment of the note, and pre-clinical and clinical activities.
Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on its LungFit® nitric oxide platform, including the LungFit® PH system, which has FDA approval and a European CE mark for specific respiratory and cardiac indications.